.jpeg)
GLP1 agonist medications Wegovy(Semaglutide) and Zepbound(Tirzepatide) are approve by the FDA for treatment of obesity in those with a body mass index (BMI) of 30 or higher or people with who are overweight with a BMI above 27 and at least one serious health complication because of their weight. Health complications include but are not limited to type 2 diabetes, hypertension, CAD, GERD, sleep apnea and osteoarthritis.
To determine if you are a candidate based on your BMI use link below to calculate your body mass index (BMI).